Article source：
Sep 21,2026
View：
4 Recently, Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), a wholly owned subsidiary of Kexing Biopharm, received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA). The notice approves clinical trials of GB20 Injection, an innovative anti-TL1A monoclonal antibody independently developed by Shenzhen Kexing, for the indication of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
GB20 Injection is a humanized monoclonal antibody targeting tumor necrosis factor superfamily member 15 (TNFSF15, also known as TL1A). It binds specifically to TL1A, blocking the intestinal inflammatory cascade and reducing inflammatory damage to the intestinal mucosa. It is intended for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
Preclinical studies show that the GB20 Injection molecule has favorable in vitro and in vivo activity. In animal models, it effectively alleviated IBD symptoms and improved intestinal function and fine structure, demonstrating both anti-inflammatory and anti-fibrotic effects. GB20 Injection has undergone long-acting engineering and exhibits favorable PK/PD properties. It has the potential to be developed as a high-concentration formulation, which is expected to reduce the frequency of clinical dosing and improve patient compliance.
In recent years, the Company has focused on oncology and autoimmune diseases and has accelerated the development of more than ten innovative drug pipelines, with multiple candidates following a dual-filing strategy in China and the United States. While strengthening its independent innovation, the Company continues to advance its internationalization, striving to become an innovative, internationally oriented biopharmaceutical enterprise and to provide more high-quality products for patients worldwide.
BACK TO LIST
Jun 29,2026
